KOD Kodiak Sciences Inc Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
18:41
Jul 20
Jul 20
Buy given best risk/reward in ophthalmology with potential to double based on deep dive in progress.
MED
14:07
Jul 15
Jul 15
Author discloses existing long position in KOD, expressing desire for larger exposure within the broader XBI bullish thesis of macro tailwinds and record sector M&A.
MED
20:04
Jul 10
Jul 10
Long KOD as author draws analogy to high-multiple ophthalmology franchises (INSM/APGE/ORKA), with Daybreak study as the key catalyst for a multi-drug, multi-indication platform; valuation deemed acceptable even on the base case.
MED
13:13
Jun 21
Jun 21
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A timing framework shows this is the window where acquirers with pre-committed capital execute; sector M&A wave across radiopharmaceuticals, MASH, IBD, and obesity validates the pattern is active.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
About KOD Analyst Coverage
Buzzberg tracks KOD (Kodiak Sciences Inc) across 1 sources. 3 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (60%). 5 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: seedy19tron.